Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review

Table 3

Number of patients developing AEs during treatment.

Authors	Year	Journal	Number of subjects	Number of deaths	Patient with at least one adverse effect at any time	Patients with treatment-related AE	Patient with severe or life-threatening AE	Discontinued from study due to ADR	Number of SAEs	No. of patients with TEAEs	Total number of TEAEs
Hassan et al. [18]	1995	J Pak Med Assoc	50	0	0	0	0	0	0	0	0
Hailu et al. [16]	2010	PLoS NTD	135	2	77	75	12	2	5	65	112
Jamil et al. [19]	2015	PLoS NTD	119	1	34	31	2	1	4	32	47
Jha et al. [20]	1998	BMJ	90	0	3	3	0	1	0	3	3
Musa et al. [21]	2010	PLoS NTD	42	0	N/A	N/A	0	0	0	N/A	48
Sinha et al. [22]	2011	Journal of Tropical Medicine	494	2	379	320	35	5	13	379	561
Sundar et al. [1]	2007	NEJM	501	2	299	298	14	5	18	299	353
Sundar et al. [23]	2009	Clinical Infectious Diseases	329	0	N/A	N/A	N/A	4	N/A	N/A	283